Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier/Saunders Country of Publication: United States NLM ID: 101231934 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1551-7136 (Print) Linking ISSN: 15517136 NLM ISO Abbreviation: Heart Fail Clin Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia : Elsevier/Saunders, c2005-
    • Subject Terms:
      Benzoxazoles*/therapeutic use ; Benzoxazoles*/pharmacology ; Amyloid Neuropathies, Familial*/drug therapy ; Amyloid Neuropathies, Familial*/complications ; Amyloid Neuropathies, Familial*/genetics ; Cardiomyopathies*/drug therapy ; Cardiomyopathies*/metabolism; Humans ; Prealbumin/genetics ; Prealbumin/metabolism
    • Abstract:
      Transthyretin amyloid cardiomyopathy (ATTR-CM) is caused by the myocardial extracellular deposition of amyloid fibrils formed from the dissociation of TTR tetramer into monomers. The rate-limiting step in TTR amyloidogenesis is the dissociation of the TTR tetramer into monomers: Tafamidis is an effective TTR-stabilizer in its native homotetrameric structure. Tafamidis is a safe and effective drug in reducing symptoms, hospitalization and mortality in accurately selected patients affected by hereditary and wild-type transthyretin amyloid cardiomyopathy.
      Competing Interests: Disclosure The authors have nothing to declare.
      (Copyright © 2024 Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: ATTR; Amyloidoses; Cardiomyopathy; Tafamidis; Transthyretin; Treatment
    • Accession Number:
      8FG9H9D31J (tafamidis)
      0 (Benzoxazoles)
      0 (Prealbumin)
    • Subject Terms:
      Amyloidosis, Hereditary, Transthyretin-Related
    • Publication Date:
      Date Created: 20240606 Date Completed: 20240606 Latest Revision: 20240606
    • Publication Date:
      20240607
    • Accession Number:
      10.1016/j.hfc.2024.03.007
    • Accession Number:
      38844304